Drug combinations are commonly used to immobilize white-tailed deer (Odocoileus virginianus) for capture or handling. Although efficacy of various compatible and complementary drugs has been tested in clinical trials with deer, extensive negative side effects, impractical drug volume, and slow recovery from immobilization sometimes make these combinations less than ideal for routine field use. We hypothesized that a combination of butorphanol, azaperone, and medetomidine (BAM) would provide safe and effective immobilization of captive white-tailed deer while minimizing these complicating factors. We tested two dosages of this drug combination (BAM-1 and BAM-2) and two dosages of a naltrexone, tolazoline, and atipamezole antagonist combination (NTA-1 and NTA-2) with captive white-tailed deer. We characterized efficacy of drug for immobilization, quality of drug induction, and recovery after drug reversal, and we compared our findings with those of previous drug trials. Complete immobilization and excellent induction quality was achieved with a low volume dosage of BAM-2. Time to drug induction and deer recumbency for BAM-2 compared favorably with results from previous trials involving xylaxine/ ketamine and medetomidine/ketamine but without risk of hyperthermia. We found no differences in time to deer recovery for NTA-1 and NTA-2, with deer treated with either combination standing by 30 min postinjection. Regardless of immobilizing drugs used, we suggest practitioners monitor for signs of circulatory deficiency in deer and provide supplemental oxygen when needed.

01 Sep 1982·Clinical and experimental immunologyQ3 · MEDICINE

Sensitivity of pre-T cells to natural thymocytotoxic autoantibodies developed in New Zealand Black mice.

Q3 · MEDICINE

Article

Author: Osawa, T ; Imai, Y

The effect of affinity purified natural thymocytotoxic autoantibodies from New Zealand Black (NZB) mice (NTA-1 and NTA-2) against pre-T cells was studied. Pre-treatment of spleen cells from nu/nu mice or bone marrow cells from DBA/2 mice with NTA-1 and complement (C) or with NTA-2 and C markedly inhibited the induction of T cell markers with a thymic extract in vitro. The effect of NTA-2 and C was abolished by absorption of NTA-2 with neuraminidase treated thymocytes, whereas its effect was not abolished by absorption with intact thymocytes. The effect of NTA-1 and C was abolished by absorption of NTA-1 with either neuraminidase treated thymocytes or intact thymocytes. The effect of NTA-2 was inhibited by lactose whereas the effect of NTA-1 was not. These results suggest that NTA-2 specifically recognizes the cell surface characteristics of pre-T cells and blocks the differentiation pathway of T cells.

01 May 1982·Journal of immunology (Baltimore, Md. : 1950)Q2 · MEDICINE

Induction of autoimmune phenomena in normal mice treated with natural thymocytotoxic autoantibody.

Q2 · MEDICINE

Article

Author: Nakanishi, A ; Osawa, T ; Imai, Y ; Nakano, T

Natural thymocytotoxic autoantibody (NTA) developed spontaneously in New Zealand Black (NZB) mice consists of two autoantibodies in terms of target cell specificity. One of the autoantibodies, NTA-2, is strongly cytotoxic only against desialized lymphocytes, whereas the other one, NTA-1, is cytotoxic against both intact thymocytes and asialolymphocytes. To study the pathogenic role of NTA in murine autoimmunity, DBA/2 mice were injected every other day with affinity-purified NTA (NTA-1, NTA-2). Control mice received normal mice sera (NMS) or saline. After 20 days of treatment, spleen cells from DBA/2 mice treated with NTA-1 or NTA-2 showed a significant increase in the number of anti-ssDNA plaque-forming cells and IgM-producing cells. Sera from NTA-treated mice showed greater DNA binding than sera from control mice did. The levels of proteinuria were moderately increased in NTA-2-treated mice. Con A responsiveness of thymocytes was markedly reduced in NTA-2-treated mice. On the other hand, Con A-activated spleen cells from both control and NTA-treated mice equally suppressed anti-SRBC antibody production in vitro, suggesting that NTA treatment didn't affect the direct precursors of suppressor T cells. Finally, prior absorption of NTA-1 by thymocytes prevented its ability to induce anti-DNA antibodies; however, prior absorption of NTA-2 by thymocytes didn't affect its activity.

100 Deals associated with NTA-1

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Discovery	DK	Nuevolution AB	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NTA-1

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation